Extracorporeal life support for primary graft dysfunction after heart transplantation by Pozzi, Matteo et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Original citation: 
Pozzi, Matteo, Bottin, Chiara, Armoiry, Xavier, Sebbag, Laurent, Boissonnat, Pascale, Hugon-
Vallet, Elisabeth, Koffel, Catherine, Flamens, Claire, Paulus, Sylvie, Fellahi, Jean Luc and 
Obadia, Jean Francois (2018) Extracorporeal life support for primary graft dysfunction after 
heart transplantation. Interactive CardioVascular and Thoracic Surgery . 
doi:10.1093/icvts/ivy157 
 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/102585                        
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions.  Copyright © 
and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable the 
material made available in WRAP has been checked for eligibility before being made 
available. 
 
Copies of full items can be used for personal research or study, educational, or not-for profit 
purposes without prior permission or charge.  Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 
page and the content is not changed in any way. 
 
Publisher’s statement: 
This is a pre-copyedited, author-produced version of an article accepted for publication in 
Interactive CardioVascular and Thoracic Surgery following peer review. The version of record 
Matteo Pozzi, Chiara Bottin, Xavier Armoiry, Laurent Sebbag, Pascale Boissonnat, Elisabeth 
Hugon-Vallet, Catherine Koffel, Claire Flamens, Sylvie Paulus, Jean Luc Fellahi, Jean Francois 
Obadia; Extracorporeal life support for primary graft dysfunction after heart transplantation, 
Interactive CardioVascular and Thoracic Surgery, , ivy157, 
https://doi.org/10.1093/icvts/ivy157 is available online at: 
https://doi.org/10.1093/icvts/ivy157  
 
A note on versions: 
The version presented here may differ from the published version or, version of record, if 
you wish to cite this item you are advised to consult the publisher’s version.  Please see the 
‘permanent WRAP url’ above for details on accessing the published version and note that 
access may require a subscription. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk 
 
 1 
Extracorporeal life support for primary graft dysfunction after heart transplantation 1 
 2 
Matteo Pozzia, Chiara Bottina, Xavier Armoiryb, Laurent Sebbagc, Pascale Boissonnatc, Elisabeth 3 
Hugon-Valletc, Catherine Koffeld, Claire Flamensd, Sylvie Paulusd, Jean Luc Fellahid, Jean Francois 4 
Obadiaa 5 
 6 
aDepartment of Cardiac Surgery, “Louis Pradel” Cardiologic Hospital, “Claude Bernard” University, 7 
Lyon, France 8 
bUniversity of Warwick, Warwick Medical School, Division of Health Sciences, Coventry, England 9 
cDepartment of Cardiology, “Louis Pradel” Cardiologic Hospital, “Claude Bernard” University, Lyon, 10 
France 11 
dDepartment of Anesthesia and ICU, “Louis Pradel” Cardiologic Hospital, “Claude Bernard” 12 
University, Lyon, France 13 
 14 
Corresponding author: 15 
Matteo Pozzi 16 
Department of Cardiac Surgery, “Louis Pradel” Cardiologic Hospital, “Claude Bernard” University, 17 
Lyon, France 18 
28, Avenue du Doyen Lépine, 69500 Bron (Lyon), France 19 
Phone: +33472129548 20 
Fax: +33472357383 21 
E-mail: mpozzi1979@gmail.com 22 
 23 
Word count: 5000 24 
25 
 2 
ABSTRACT 26 
Objectives. Survival after heart transplantation (HTx) is steadily improving but primary graft 27 
dysfunction (PGD) is still a leading cause of death. Medical management seems useful in mild or 28 
moderate PGD while extracorporeal life support (ECLS) could be suggested for severe PGD refractory 29 
to conventional treatment. Our aim is to present the results of ECLS for PGD after HTx at a single-30 
centre experience. 31 
Methods. We performed an observational analysis of our local database. According to the International 32 
Society for Heart and Lung Transplantation classification, patients were divided into a left and 33 
biventricular failure (PGD-LV) or isolated right ventricular failure (PGD-RV) group. The primary end-34 
point was survival to hospital discharge. 35 
Results. Between January 2010 and December 2016, 38 patients presented PGD (PGD-LV n=22, 58%; 36 
PGD-RV n=16, 42%) requiring ECLS support. The mean age was 50.8 ± 12.4 years with 79% of males. 37 
Baseline characteristics were comparable between the two groups. PGD-LV patients displayed a 38 
significantly higher mortality rate on ECLS support as opposed to PGD-RV patients (46% vs. 13%, 39 
p=0.033). The complications’ rate during ECLS support was comparable between the two groups. 40 
Twenty-three (61%) patients were successfully weaned from ECLS (PGD-LV=50% vs. PGD-RV=75%, 41 
p=0.111) after a mean support of 9.0 ± 6.4 days. Seventeen (45%) patients survived to hospital 42 
discharge (PGD-LV=41% vs. PGD-RV=50%, p=0.410). 43 
Conclusions. In case of severe PGD with various manifestations of ventricular failure refractory to 44 
conventional treatment, ECLS can be considered as a feasible option with a satisfactory survival in this 45 
critically ill population. 46 
 47 
Keywords: heart transplantation, primary graft dysfunction, left-sided heart failure, right-sided heart 48 
failure, extracorporeal membrane oxygenation. 49 
50 
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INTRODUCTION 51 
Although overall survival after heart transplantation (HTx) has continued to improve in the last three 52 
decades, primary graft dysfunction (PGD) is still a leading cause of death in the early post-transplant 53 
period [1]. The relevant literature of PGD shows heterogeneous results and conclusions owing to 54 
inconsistent definitions of PGD used by different authors [2]. This lack of standardization of the 55 
definition, diagnostic criteria and treatment strategies led the International Society for Heart and Lung 56 
Transplantation (ISHLT) to develop a consensus document in 2014 [3]. 57 
PGD is now clearly differentiated by secondary graft dysfunction where a specific cause - i.e. 58 
hyperacute rejection, pulmonary hypertension or surgical complications - could be recognized. 59 
Moreover the diagnosis of PGD must be performed within 24 hours after the completion of HTx and 60 
should distinguish between left and biventricular failure (PGD-LV) or isolated right ventricular failure 61 
(PGD-RV). Finally the introduction of a grading system of PGD severity could guide the subsequent 62 
decision-making algorithm [3]. Medical management seems useful in mild or moderate PGD while 63 
extracorporeal life support (ECLS) could be suggested as a therapeutic option for those severe cases of 64 
PGD that are refractory to maximal conventional treatment including inotropes, vasodilators and nitric 65 
oxide [4-15]. 66 
We aimed to report the results of ECLS for PGD after HTx according to the ISHLT classification. 67 
 68 
MATERIALS AND METHODS 69 
 70 
Study design 71 
We undertook an observational analysis of our local database of ECLS implantation for PGD after HTx. 72 
Authorization from an ethics committee and written informed consent from participants were not 73 
required owing to national regulations on “non-interventional clinical research” (articles L.1121-1 and 74 
R.1121-2 of the French Public Health Code). 75 
 76 
Patient population 77 
Adult patients who received an ECLS for PGD after HTx at our institution from January 2010 to 78 
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December 2016 were included. We excluded patients: 1) undergoing HTx and aged <18 years (n=29); 79 
2) requiring ECLS for graft dysfunction secondary to isolated pulmonary hypertension (n=2); 3) 80 
receiving ECLS more than 24 hours after HTx completion (n=4). PGD was defined according to the 81 
ISHLT criteria [3]. In particular, severe PGD-LV was defined as the need of left or biventricular 82 
mechanical circulatory support. Conversely, there were no grades for the severity of PGD-RV because 83 
isolated right ventricular failure can often be more difficult to quantify. 84 
 85 
Surgical technique 86 
ECLS was implanted in the event of: 1) inability to wean the patient from cardiopulmonary bypass 87 
despite inotropic support, 2) refractory cardiogenic shock in the postoperative period within 24 hours 88 
after completion of HTx. Failure of weaning from cardiopulmonary bypass was assessed by 89 
intraoperative transesophageal echocardiography (left ventricular ejection fraction ≤40% and/or 90 
evidence of right ventricular dysfunction) coupled to right heart catheterization (cardiac index <2 91 
L/min/m2). Cardiogenic shock was defined as hypotension (systolic blood pressure <90 mmHg) despite 92 
adequate filling status with signs of hypoperfusion [16]. The implantation of ECLS could be performed 93 
in a peripheral or intrathoracic configuration and the choice was left to the surgeon’s discretion. 94 
Peripheral ECLS was implanted surgically. Venous and arterial cannulae were placed using a modified 95 
Seldinger technique after surgical exposure of the femoral vessels at the groin. As per institutional 96 
policy, an arterial catheter was systematically placed distally to the entry site of the arterial cannula to 97 
prevent lower limb ischemia. In the intrathoracic or central ECLS, the venous drainage was obtained 98 
using either a direct cannulation of the right atrium or a percutaneous femoral venous cannula. The 99 
arterial reinjection was placed in the ascending aorta. Left ventricular unloading, if necessary, was 100 
accomplished after cannulation of the right superior pulmonary vein or left ventricular apex. The 101 
cannulae were tunnelled in the subxyphoid or subcostal region and the sternum was completely closed. 102 
The ECLS circuit consisted also of venous and arterial heparin-bounded tubing, a membrane oxygenator 103 
(Quadrox Bioline, Jostra-Maquet, Orléans, France), a centrifugal pump (Rotaflow, Jostra-Maquet, 104 
Orléans, France) and an oxygen/air blender (Sechrist Industries, Anaheim, CA, USA). 105 
 106 
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ECLS management 107 
As previously described [17], ECLS flow was initially set at the theoretical cardiac output owing to the 108 
patient’s body surface area. However an inotropic support with dobutamine was used in order to 109 
maintain a left ventricular ejection with aortic valve opening. Moreover a vasopressor support with 110 
norepinephrine was usually added with a target mean blood pressure of 60-80 mmHg. After admission 111 
to our intensive care unit, the anticoagulation with unfractioned heparin was usually started 6 hours after 112 
the completion of HTx if the surgical bleeding from the chest drains was less than 50 ml/hour. Target 113 
unfractionated heparin anti-Xa factor activity was maintained between 0.30 and 0.35 IU/ml during 114 
ECLS support. Serial transoesophageal echocardiography was performed after progressive reduction of 115 
ECLS flow to assess the myocardial recovery. Patients stable during reduction trials and with left 116 
ventricular ejection fraction > 25% and time-velocity integral > 10 cm were weaned from ECLS [18]. 117 
Right ventricular function was considered recovered when: 1) systemic arterial pressure remained stable 118 
without the augmentation of central venous pressure; 2) major inotropic support or need for escalation 119 
of inotropic support were not required; 3) a transthoracic echocardiography showed satisfactory right 120 
ventricular systolic function without dilatation. Right-sided hemodynamic parameters were not 121 
considered, because their interpretation under ECLS support is complicated. If the weaning trial was 122 
hemodynamically tolerated and the echocardiographic criteria were fulfilled, the decannulation 123 
procedure was performed in a surgical manner with reopening of the operative field at the groin or chest 124 
depending on the ECLS configuration. Successful weaning was defined as ECLS decannulation without 125 
the need for ECLS reinsertion or mortality within 48 hours. In patients without complete myocardial 126 
recovery, cardiac retransplantation could be considered as a rescue therapeutic option. Conversely, 127 
ECLS support was considered futile and then stopped in the presence of multiple organ failure or brain 128 
death. 129 
 130 
Outcome and statistical analysis 131 
Preoperative, perioperative and postoperative data were retrieved from the computerized medical charts 132 
of our hospital. Moreover, heart donors’ data were collected from the French regulatory agency of 133 
transplantation (“The Agence of Biomedecine”). Patients were divided into a left and biventricular 134 
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failure (PGD-LV) or isolated right ventricular failure (PGD-RV) group according to the 135 
echocardiographic and hemodynamic parameters defined in the ISHLT classification [3]. The secondary 136 
endpoints were complications rate during ECLS support, successful weaning rate from ECLS and short-137 
term outcome. Neurological complications included seizure, cerebral infarction and intracerebral 138 
hemorrhage. Only infections occurring >24 hours after ECLS initiation and within 48 hours after ECLS 139 
discontinuation were defined as ECLS-associated [19]. 140 
Statistical analysis was performed with SPSS software, version 24.0 (IBM Corp., Armonk, NY, USA). 141 
Categorical variables were presented as counts and percentages and compared by using the Pearson’s 142 
chi-squared test or Fisher’s exact test (>20% of expected counts with <5 counts). Continuous variables 143 
were presented as mean ± standard deviation and compared using Student’s t-test or Mann–Whitney U-144 
test depending on their normality, which was assessed by the Kolmogorov–Smirnov test. Survival was 145 
calculated with the use of Kaplan–Meier analysis and compared using the log-rank test. A level of 0.05 146 
was used to test for significance. 147 
 148 
RESULTS 149 
 150 
Baseline characteristics 151 
Of the 212 patients who had orthotopic HTx, 38 (18%) developed PGD (PGD-LV n=22, 58%; PGD-RV 152 
n=16, 42%) requiring ECLS support and met our selection criteria. The mean age was 50.8 ± 12.4 153 
(range, 22-64) years with 79% of males. Table 1 shows the preoperative characteristics. Ischemic 154 
cardiomyopathy was the most frequent (48%) diagnosis leading to HTx and 14 (38%) patients were 155 
bridged to HTx with a temporary (n=6, 16%) or long-term (n=8, 21%) mechanical circulatory support. 156 
Baseline characteristics were comparable between both groups. The mean age of heart donors was 41.3 157 
± 12.6 (range, 21-63) years with 68% of males. Table 2 summarises the characteristics of heart donors. 158 
The heart donors’ characteristics were comparable between both groups. In particular, there was no 159 
difference in term of sex mismatch (donor female to recipient male). Table 3 displays the baseline 160 
biological and hemodynamic evaluation of our patient population. The biological profile was typical of 161 
end-stage heart failure patients. PGD-LV patients showed numerically higher total bilirubin levels 162 
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compared to PGD-RV patients but the difference did not reach statistical significance (28.4 vs. 16.9 163 
μmol/L, p=0.069). 164 
 165 
Short-term outcomes 166 
Table 4 shows the operative and postoperative outcomes of our study population. ECLS was implanted 167 
directly at the operatory theatre when weaning from cardiopulmonary bypass was not possible in 30 168 
(79%) patients (PGD-LV=86% vs. PGD-RV=69%, p=0.189). No patients underwent ECLS 169 
implantation during cardiopulmonary resuscitation. Peripheral ECLS was used in 25 (66%) patients 170 
(PGD-LV=64% vs. PGD-RV=69%, p=0.743). PGD-LV patients displayed a significantly higher 171 
mortality rate on ECLS support compared to those with PGD-RV (46 vs. 13%, p=0.033). The rate of 172 
complications during ECLS support was comparable between both groups. Twenty-three (61%) patients 173 
were successfully weaned from ECLS (PGD-LV=50% vs. PGD-RV=75%, p=0.111) after a mean 174 
support of 9.0 ± 6.4 (range, 3-32) days (PGD-LV=7.5 days vs. PGD-RV=9.3 days, p=0.429). One (3%) 175 
patient died in the first 24 hours after ECLS weaning for multi-organ failure while two (5%) were 176 
bridged to cardiac retransplantation owing to the absence of myocardial recovery. Seventeen (45%) 177 
patients survived to hospital discharge (PGD-LV=41% vs. PGD-RV=50%, p=0.410). Figure 1 depicts 178 
the outcome of our study population. Overall survival was 43% (95%CI 27.2 - 59.4%; 13 remaining 179 
observations) at 1 year. The log-rank test showed no significant difference on overall survival between 180 
the two groups (median overall survival in the PGD-LV group=11 days, 95%CI 0-39; median overall 181 
survival in the PGD-RV group=201 days, 95%CI 0-796; p=0.315; Figure 2). 182 
 183 
DISCUSSION 184 
PGD is a life-threatening complication after HTx that negatively affects short- and long-term outcome. 185 
It accounts for approximately 40% of deaths within 30 days of cardiac transplantation [20]. Moreover 186 
overall late survival is significantly lower in patients experiencing PGD [7,8,10,11,14,21]. The 187 
pathophysiology is multifactorial and several risk factors involving the donor, recipient and surgical 188 
procedure have been identified over time [3,14,21]. 189 
The incidence of severe PGD requiring ECLS was quite high (18%) in our experience. Although the 190 
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definitions of PGD were heterogeneous making comparisons difficult to carry out, this incidence was 191 
consistent with previous reports. In papers providing detailed information the incidence of PGD 192 
supported with ECLS ranged between 7% and 23% [5,7-15,21]. Interestingly, D’Alessandro et al. found 193 
a temporal trend of PGD after HTx. The raising of incidence in more recent years was explained by an 194 
evolving profile of recipients and donors, with more critically ill patients transplanted with marginal 195 
donors [7]. This increasing rate of PGD after HTx reflects a more general effort of every transplant team 196 
to overcome the shortage of heart’s donors. This effort is also witnessed by our prolonged total ischemic 197 
time. Allograft ischemic time affects predominantly early outcomes and ischemic time <4 hours is 198 
associated with considerably higher survival [22]. The high incidence of severe PGD requiring ECLS in 199 
our series could be partially explained by the presence of several well-known risk factors like older 200 
donor age [22], longer total ischemic time and high rate of preoperative short- and long-term mechanical 201 
circulatory support, previous sternotomy and emergency transplant [3]. 202 
Our analysis showed that ECLS provided a survival to hospital discharge of 45%. These results compare 203 
favourably with other previous series that reported survivals to hospital discharge between 44% and 204 
81% [5,7,8,10-15,21]. In only one small study (11 patients) this outcome improved to 91% [6] while 205 
other investigators reached a survival to hospital discharge of 82% adopting a systematic ECLS 206 
implantation in the setting of known preceding donor cardiac dysfunction [9]. This extreme variability 207 
in survival across studies could be partially explained by the complex and multifactorial 208 
physiopathology of PGD after HTx, as opposed to other conditions with a high potential of myocardial 209 
recovery and more reproducible ECLS results such as drug intoxication and myocarditis. 210 
ECLS was most frequently implanted directly at the operatory theatre and in a peripheral configuration. 211 
Our institutional policy is to be as aggressive as possible in the implantation of ECLS before the onset 212 
of end-organ dysfunction. Interestingly, of the 8 patients who were not implanted directly at the 213 
operatory theatre, 6 (75%) did not survive to hospital discharge. Prompt ECLS implantation could 214 
reduce the dose of inotropic support, which increases myocardial oxygen consumption and limits the 215 
chances of myocardial recovery. Moreover, we prefer a femoro-femoral rather than a central ECLS as 216 
its decannulation does not need a sternal re-entry, which has a potentially increased risk of bleeding and 217 
infection. However, any previous attempt to compare central and peripheral ECLS failed to find any 218 
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significant difference in outcomes with the only exception of an increased rate of lower limb ischemia in 219 
the femoral group [7,21]. Lower limb ischemia was encountered in 12% of our peripheral ECLS 220 
subgroup and this complication rate is comparable to that reported in the literature [23-25] and in 221 
previous reports of ECLS for PGD after HTx [7,8]. 222 
We observed a disproportionate rate (approximately 50%) of surgical re-exploration for bleeding. This 223 
complication rate was experienced in 26-38% of patients in previous analyses [7,8,14]. A possible 224 
explanation for this bleeding complications could be the higher proportion (21%) of patients bridged to 225 
HTx with a long-term mechanical circulatory support. 226 
In our study population left and biventricular failure was the leading (58%) manifestation of PGD after 227 
HTx. Despite a comparable preoperative profile between both groups, PGD-LV patients displayed a 228 
significantly higher mortality rate on ECLS support as opposed to PGD-RV patients. The main cause of 229 
death (6 out of 10 patients) in the PGD-LV group was multi-organ failure. However, there was no 230 
difference on overall survival between both groups at hospital discharge and short-term follow-up. In 231 
fact four patients in the PGD-RV group were weaned from ECLS support but did not survive to hospital 232 
discharge. Conversely in a recent paper by Loforte et al. evaluating early graft failure (primary and 233 
secondary according to the ISHLT consensus document) after HTx, the ECLS group was characterized 234 
mainly by biventricular dysfunction (93%) and, rarely, by isolated right ventricular failure (7%) [14]. 235 
Based on our results and those from previous reports [4-15], ECLS can be considered as a feasible 236 
option in the setting of PGD after HTx as: 1) the implantation – especially in the peripheral 237 
configuration – is easy and quick, 2) it allows a rapid hemodynamic stabilization with progressive end-238 
organ function improvement and 3) it represents a reasonable solution in term of cost-effectiveness in 239 
such a critically ill population. Cardiac retransplantation could no more be considered an acceptable 240 
option because of the shortage of donors entailing ethical considerations and the dismal survival. In our 241 
study two patients were addressed to cardiac retransplantation in the absence of myocardial recovery 242 
during ECLS support and died. Recently Takeda et al. conducted a comparative analysis between ECLS 243 
(n=27) and temporary ventricular assist devices (n=17) in patients with severe PGD [15]: ECLS was 244 
associated with fewer postoperative complications, higher graft recovery rate and lower in-hospital 245 
mortality compared to ventricular assist devices. Taghavi et al. analysed retrospectively their experience 246 
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with either right ventricular assist device (n=15) or ECLS (n=13) to treat acute right ventricular failure 247 
after HTx [26]. Although no difference in survival to hospital discharge was observed between the two 248 
groups, the weaning rate and graft survival were significantly better in the ECLS group. In fact right 249 
ventricular assist devices could not allow a successful recovery of graft function and most patients either 250 
died during mechanical support (47%) or underwent urgent heart retransplantation (40%). 251 
 252 
Study limitations 253 
The present study displays several limitations. The small sample size represents a limiting factor that 254 
could undermine the statistical power of our analysis. Our conclusions are gathered from a single-centre 255 
observational experience and thus may not be generalizable to other settings. The ISHLT criteria for the 256 
definition and classification of PGD were applied retrospectively to our local database, with obvious 257 
intrinsic limitations. We did not consider as a comparison group patients with PGD not requiring ECLS 258 
or supported with other types of mechanical circulatory support. From a statistical standpoint the 259 
survival estimates have been evaluated from a very limited sample size of patients, which leads to wide 260 
95% confidence intervals around the estimates overlapping between both groups. The absence of 261 
statistical difference using the log-rank test translates the lack of power of our study. With regards to 262 
survival analysis, our results can be considered as inconclusive. 263 
 264 
CONCLUSION 265 
PGD is still a serious complication in the immediate postoperative period of cardiac transplantation. In 266 
case of severe PGD refractory to conventional treatment ECLS can be considered as a feasible option 267 
with an acceptable complications’ rate and a satisfactory survival in this critically ill population. Further 268 
studies with larger study populations are however mandatory in order to best define the prognostic role 269 
of the ISHLT classification. 270 
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FIGURE LEGENDS 281 
 282 
Figure 1. Flow diagram of the outcome of the study population. ECLS = extracorporeal life support, 283 
PGD = primary graft dysfunction, HTx = heart transplantation, PGD-LV = left and biventricular 284 
primary graft dysfunction, PGD-RV = isolated right ventricular primary graft dysfunction. 285 
 286 
Figure 2. Survival of ECLS for PGD after HTx. A) Group analysis, B) Total population. ECLS = 287 
extracorporeal life support, PGD = primary graft dysfunction, HTx = heart transplantation, PGD-LV = 288 
left and biventricular primary graft dysfunction, PGD-RV = isolated right ventricular primary graft 289 
dysfunction. 290 
291 
 13 
Table 1. Preoperative characteristics. 292 
Variable Overall 
n=38 
PGD-LV 
n=22 
PGD-RV 
n=16 
p-value 
Age, years 50.8 ± 
12.4 
50.4 ± 10.5 51.4 ± 14.9 0.814 
Male sex, n (%) 30 (79) 18 (82) 12 (75) 0.453^ 
BSA, m2 1.8 ± 0.2 1.8 ± 0.2 1.7 ± 0.2 0.265 
BMI, Kg/m2 24.7 ± 3.8 25.4 ± 3.5 23.7 ± 4.1 0.196 
CV risk factors, n (%) 
 Hypertension 
 Diabetes 
 Dyslipidaemia 
 History of smoking 
 Obesitya 
 
10 (26) 
8 (21) 
11 (29) 
20 (53) 
4 (11) 
 
6 (27) 
6 (27) 
6 (27) 
11 (50) 
3 (14) 
 
4 (25) 
2 (13) 
5 (31) 
9 (56) 
1 (6) 
 
0.589^ 
0.245^ 
0.790# 
0.480# 
0.433^ 
Previous cardiac surgery, n 
(%) 
17 (45) 9 (41) 8 (50) 0.578 
ICD, n (%) 23 (61) 12 (55) 11 (69) 0.376# 
CRT, n (%) 10 (26) 6 (27) 4 (25) 0.589^ 
Diagnosis, n (%) 
 ICM 
 DCM 
 Other 
 
18 (48) 
10 (26) 
10 (26) 
 
11 (50) 
4 (18) 
7 (32) 
 
7 (44) 
6 (38) 
3 (19) 
0.369^  
Waiting list time, months 41.1 ± 
207.2 
5.5 ± 7.7 13.3 ± 24.2 0.228 
High emergency waiting 
list, n (%) 
25 (66) 14 (64) 11 (69) 0.743# 
Clinical status, n (%)     
 14 
 Inotropes 
 Mechanical ventilation 
 IABP 
 ECLS 
 Long-term MCS 
15 (39) 
5 (13) 
10 (26) 
6 (16) 
8 (21) 
9 (41) 
4 (18) 
6 (27) 
5 (23) 
6 (27) 
6 (38) 
1 (6) 
4 (25) 
1 (6) 
2 (13) 
0.832# 
0.286^  
0.589^  
0.180^  
0.245^  
aObesity was defined as BMI > 30 Kg/m2. 293 
For categorical variables, # denotes p-value obtained with the chi-square test while ^ with the Fisher’s 294 
exact test. 295 
PGD-LV = left and biventricular primary graft dysfunction, PGD-RV = isolated right ventricular 296 
primary graft dysfunction, BSA = body surface area, BMI = body mass index, CV = cardiovascular, 297 
CVA = cerebrovascular accident, ICD = implantable cardioverter defibrillator, CRT = cardiac 298 
resynchronization therapy, ICM = ischemic cardiomyopathy, DCM = dilated cardiomyopathy, IABP = 299 
intra-aortic balloon pump, ECLS = extracorporeal life support, MCS = mechanical circulatory support. 300 
301 
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Table 2. Characteristics of heart donors. 302 
Variable Overall 
n=38 
PGD-LV 
n=22 
PGD-RV 
n=16 
p-value 
Age, years 41.3 ± 
12.6 
41.7 ± 12.8 40.9 ± 12.8 0.841 
Male sex, n (%) 26 (68) 15 (68) 11 (69) 0.970# 
BSA, m2 1.9 ± 0.2 1.9 ± 0.2 1.8 ± 0.2 0.450 
BMI, Kg/m2 25.3 ± 4.8 25.2 ± 4.1 25.5 ± 5.7 0.838 
Vasopressor support, n (%) 34 (90) 20 (91) 14 (88) 0.567^ 
LVEF, % 62.1 ± 6.2 61.3 ± 5.5 63.0 ± 7.2 0.424 
Sex mismatch (recipient M, 
donor F), n (%) 
9 (24) 5 (23) 4 (25) 0.584^  
Cause of death, n (%) 
 Trauma 
 CVA 
 Other 
 
15 (39) 
11 (29) 
12 (32) 
 
10 (45) 
7 (32) 
5 (23) 
 
5 (31) 
4 (25) 
7 (44) 
0.447^  
For categorical variables, # denotes p-value obtained with the chi-square test while ^ with the Fisher’s 303 
exact test. 304 
PGD-LV = left and biventricular primary graft dysfunction, PGD-RV = isolated right ventricular 305 
primary graft dysfunction, BSA = body surface area, BMI = body mass index, LVEF = left ventricular 306 
ejection fraction, M = male, F = female, CVA = cerebrovascular accident. 307 
308 
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Table 3. Baseline biological and hemodynamic evaluation. 309 
Variable Overall 
n=38 
PGD-LV 
n=22 
PGD-RV 
n=16 
p-value 
Hemoglobin, g/dL 11.5 ± 2.3 11.3 ± 2.5 11.7 ± 2.0 0.588 
Platelets, 109/L 201.0 ± 90.2 202.0 ± 95.7 199.6 ± 85.2 0.937 
WBC, 109/L 9.3 ± 4.2 9.2 ± 3.1 9.3 ± 5.4 0.990 
INR 1.8 ± 1.0 1.9 ± 1.0 1.8 ± 0.9 0.605 
BUN, mmol/L 12.5 ± 9.0 11.9 ± 8.1 13.4 ± 10.3 0.611 
Creatinine, μmol/L 116.6 ± 15.5 110.4 ± 40.3 124.5 ± 61.9 0.430 
Total bilirubin, μmol/L 23.6 ± 21.6 28.4 ± 26.9 16.9 ± 7.7 0.069 
ASAT, U/L 83.0 ± 137.0 79.2 ± 130.9 88.1 ± 149.1 0.847 
ALAT, U/L 81.5 ± 169.2 95.0 ± 209.6 63.1 ± 92.1 0.573 
     
sPAP, mmHg 46.3 ± 16.7 44.7 ± 18.5 48.6 ± 13.8 0.552 
mPAP, mmHg 30.3 ± 11.4 29.8 ± 12.4 31.0 ± 10.5 0.798 
TPG, mmHg 11.6 ± 6.7 11.4 ± 8.3 11.8 ± 3.1 0.929 
PVR, Wood units 2.5 ± 1.5 2.3 ± 1.4 2.9 ± 1.7 0.337 
PGD-LV = left and biventricular primary graft dysfunction, PGD-RV = isolated right ventricular 310 
primary graft dysfunction, WBC = white blood cells, INR = international normalized ratio, BUN = 311 
blood urea nitrogen, ASAT = aspartate aminotransferase, ALAT = alanine aminotransferase, sPAP = 312 
systolic pulmonary artery pressure, mPAP = mean pulmonary artery pressure, TPG = transpulmonary 313 
gradient, PVR = pulmonary vascular resistance. 314 
315 
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Table 4. Operative and postoperative outcomes. 316 
Variable Overall 
n=38 
PGD-LV 
n=22 
PGD-RV 
n=16 
p-value 
Total ischemic time, min 273.6 ± 57.8 280.9 ± 66.4 263.6 ± 43.2 0.369 
Mortality on ECLS, n (%) 12 (32) 10 (45) 2 (13) 0.033 
Complications on ECLS, 
n (%) 
 Lower limb ischemia 
 Neurological 
 Renal replacement 
therapy 
 Surgical re-exploration 
 Infection 
 
 
3 (8) 
5 (13) 
25 (66) 
 
20 (53) 
14 (37) 
 
 
2 (9) 
3 (14) 
14 (64) 
 
12 (55) 
7 (32) 
 
 
1 (6) 
2 (13) 
11 (69) 
 
8 (50) 
7 (44) 
 
 
0.621 
0.654 
0.743 
 
0.520 
0.452 
Successful weaning rate, n 
(%) 
23 (61) 11 (50) 12 (75) 0.111 
Survival to hospital 
discharge, n (%) 
17 (45) 9 (41) 8 (50) 0.410 
Bold indicates p value < 0.05. 317 
PGD-LV = left and biventricular primary graft dysfunction, PGD-RV = isolated right ventricular 318 
primary graft dysfunction, ECLS = extracorporeal life support. 319 
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